Breaking News

Lonza Launches GS Effex Cell Line for Therapeutic Antibodies

Provides a solution for therapeutic development from discovery stage research through to commercial manufacturing.

Lonza launched its new GS Effex cell line for the development of therapeutic antibodies with enhanced potency. The GS Effex cell line was developed to meet pressing market needs originating from the shift towards more sophisticated therapeutic antibodies. Derived from Lonza’s leading GS Xceed cell line, GS Effex fits effectively into Lonza platforms. Combined with good cell growth and the ability to produce therapeutic antibodies with increased potency, the new cell line is for therapeutic de...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters